TGFB1 and Fuchs endothelial corneal dystrophy: The consistency between these in vitro and in vivo findings supports the hypothesis that E2 may ameliorate FECD pathology by modulating the TGF-β/Smad–EMT–ECM axis in corneal endothelial cells.